Duke lupus registry for people with lupus
Part of Immune system & allergy, Skin clinical trials.
This trial is a registry that follows people with lupus to help Duke researchers learn about the disease and care. You may be able to join if you’re seen by a Duke rheumatologist and can come to follow-up visits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with lupus (systemic lupus or cutaneous lupus)
- You are currently a patient of a rheumatologist at Duke University Medical Center
- You can travel to Duke for follow-up visits
- You can speak and understand English
- You can give informed consent (you’re able to agree to participate)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is a pregnancy and health registry for women with autoimmune (immune system) conditions who are trying to become pregnant or are already pregnant. It helps researchers better understand pregnancy outcomes and health needs in autoimmune disease.
This registry tracks the safety and effectiveness of lupus treatments over time. If you have SLE and are starting a new treatment or were recently diagnosed, joining helps doctors learn which medicines work best.
This research study aims to better understand systemic lupus erythematosus (SLE), an autoimmune disease where the body's immune system attacks its own tissues. Researchers will evaluate patients with lupus, study genetic factors, and perform optional imaging tests to learn how the disease affects blood vessels and the heart.
This study follows people with systemic lupus erythematosus (an autoimmune disease) who are seen in a special clinic. It aims to track their health over time.
This study looks at the long-term health of people with lupus. It aims to understand how the disease progresses over time.
This study tests whether a specific lupus “low disease activity” target (called LLDAS) works the same way in people across the Asia-Pacific region. It may help doctors use clearer goals to track how well lupus is controlled.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.